SG11201607095RA - Antisense nucleic acids - Google Patents

Antisense nucleic acids

Info

Publication number
SG11201607095RA
SG11201607095RA SG11201607095RA SG11201607095RA SG11201607095RA SG 11201607095R A SG11201607095R A SG 11201607095RA SG 11201607095R A SG11201607095R A SG 11201607095RA SG 11201607095R A SG11201607095R A SG 11201607095RA SG 11201607095R A SG11201607095R A SG 11201607095RA
Authority
SG
Singapore
Prior art keywords
nucleic acids
antisense nucleic
antisense
acids
nucleic
Prior art date
Application number
SG11201607095RA
Inventor
Tatsushi Wakayama
Haruna Seo
Youhei Satou
Shin Ichi Takeda
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co Ltd
Nat Ct Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd, Nat Ct Neurology & Psychiatry filed Critical Nippon Shinyaku Co Ltd
Publication of SG11201607095RA publication Critical patent/SG11201607095RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
SG11201607095RA 2014-03-12 2015-03-11 Antisense nucleic acids SG11201607095RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014048897 2014-03-12
PCT/JP2015/057180 WO2015137409A1 (en) 2014-03-12 2015-03-11 Antisense nucleic acid

Publications (1)

Publication Number Publication Date
SG11201607095RA true SG11201607095RA (en) 2016-10-28

Family

ID=54071850

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607095RA SG11201607095RA (en) 2014-03-12 2015-03-11 Antisense nucleic acids

Country Status (30)

Country Link
US (4) US9988629B2 (en)
EP (2) EP3118311B1 (en)
JP (1) JP6606488B2 (en)
KR (1) KR102335801B1 (en)
CN (2) CN106459955B (en)
AU (2) AU2015227733B2 (en)
BR (1) BR112016020618B1 (en)
CA (1) CA2939948A1 (en)
CY (1) CY1121322T1 (en)
DK (1) DK3118311T3 (en)
ES (1) ES2710802T3 (en)
HR (1) HRP20190235T1 (en)
HU (1) HUE042283T2 (en)
IL (1) IL247663B (en)
LT (1) LT3118311T (en)
MX (1) MX2016011538A (en)
MY (1) MY193708A (en)
NZ (1) NZ724836A (en)
PH (1) PH12016501761B1 (en)
PL (1) PL3118311T3 (en)
PT (1) PT3118311T (en)
RS (1) RS58573B1 (en)
RU (2) RU2702424C2 (en)
SG (1) SG11201607095RA (en)
SI (1) SI3118311T1 (en)
TR (1) TR201901939T4 (en)
TW (2) TW201945383A (en)
UA (1) UA120849C2 (en)
WO (1) WO2015137409A1 (en)
ZA (1) ZA201605864B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988629B2 (en) * 2014-03-12 2018-06-05 Nippon Shinyaku Co., Ltd. Antisense nucleic acids
MY185390A (en) 2015-09-15 2021-05-17 Nippon Shinyaku Co Ltd Antisense nucleic acids
TW201722439A (en) 2015-10-09 2017-07-01 波濤生命科學有限公司 Oligonucleotide compositions and methods thereof
AU2017290231A1 (en) 2016-06-30 2019-02-07 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP3485015A4 (en) * 2016-07-15 2020-07-29 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dystrophin transcript
BR112019012647A2 (en) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc exon jump oligomer conjugates for muscular dystrophy
HUE060065T2 (en) 2016-12-19 2023-01-28 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
CN110636866A (en) 2016-12-19 2019-12-31 萨勒普塔医疗公司 Exon skipping oligomer conjugates for muscular dystrophy
CN110381980A (en) * 2017-01-06 2019-10-25 艾维迪提生物科学有限责任公司 The method that nucleic acid-peptide composition and inducing exon are skipped
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
WO2019060862A1 (en) * 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US20210346290A1 (en) * 2018-06-13 2021-11-11 Kawasaki Institute Of Industrial Promotion POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDa
JP2021532831A (en) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. Muscle-targeted complexes and their use to treat dystrophin disorders
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3108289A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210091180A (en) * 2018-11-02 2021-07-21 바이오마린 테크놀로지스 비.브이. Bispecific antisense oligonucleotides for dystrophin exon skipping
WO2020118246A1 (en) * 2018-12-06 2020-06-11 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3936135A4 (en) * 2019-01-30 2023-03-15 National Center Of Neurology And Psychiatry Nucleic acid delivery complex
WO2021172498A1 (en) 2020-02-28 2021-09-02 日本新薬株式会社 Antisense nucleic acid inducing skipping of exon 51
CA3216839A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
ATE220407T1 (en) 1989-12-20 2002-07-15 Antivirals Inc UNCHARGED MORPHOLINE BASED POLYMERS WITH CHIRAL PHOSPHORUS CONTAINING BRIDGES BETWEEN SUBUNITS
JP2924179B2 (en) 1993-02-19 1999-07-26 日本新薬株式会社 Glycerol derivatives, devices and pharmaceutical compositions
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
ES2554660T3 (en) * 2002-11-25 2015-12-22 Masafumi Matsuo ENA nucleic acid drugs that modify splicing in mRNA precursors
US7807816B2 (en) * 2004-06-28 2010-10-05 University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
JPWO2006038608A1 (en) 2004-10-05 2008-05-15 日本新薬株式会社 Oligo double-stranded RNA and pharmaceutical composition
CA2605512A1 (en) * 2005-04-22 2006-10-26 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
JP5056413B2 (en) 2005-05-30 2012-10-24 日本新薬株式会社 Method for producing nucleic acid-containing complex preparation
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
RU2418068C2 (en) * 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Chemically modified short interfering nucleic acid molecules that mediate rna interference
EP1963538A2 (en) * 2005-11-30 2008-09-03 Guild Associates, Inc. Differentially fluorescent yeast biosensors for the detection and biodegradation of chemical agents
WO2008096690A1 (en) 2007-02-05 2008-08-14 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
CN101896186A (en) 2007-10-26 2010-11-24 莱顿教学医院 The mode and the method for antagonism disorder of muscle
CA2884340C (en) 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
KR20230025924A (en) * 2008-10-24 2023-02-23 사렙타 쎄러퓨틱스 인코퍼레이티드 Multiple exon skipping compositions for dmd
DK2344637T4 (en) * 2008-10-27 2018-04-23 Biomarin Tech Bv Methods and means for efficiently skipping exon 45 in Duchenne muscular dystrophy pre-mRNA
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2499249B1 (en) * 2009-11-12 2018-08-08 The University Of Western Australia Antisense molecules and methods for treating pathologies
KR101981705B1 (en) 2010-05-28 2019-05-24 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
IT1400425B1 (en) 2010-06-08 2013-05-31 Amsterdam Molecular Therapeutics Bv MODIFIED SNRNAS FOR USE IN THERAPY.
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
CN103501793A (en) * 2011-02-08 2014-01-08 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) Antisense oligonucleotides
CN103619356B (en) * 2011-05-05 2017-09-12 萨勒普塔医疗公司 Peptide oligonucleotide conjugates
CN110055243B (en) * 2011-12-28 2024-03-26 日本新药株式会社 Antisense nucleic acid
US9988629B2 (en) * 2014-03-12 2018-06-05 Nippon Shinyaku Co., Ltd. Antisense nucleic acids

Also Published As

Publication number Publication date
NZ724836A (en) 2022-07-01
PL3118311T3 (en) 2019-09-30
JPWO2015137409A1 (en) 2017-04-06
PH12016501761A1 (en) 2016-11-07
DK3118311T3 (en) 2019-03-11
IL247663A0 (en) 2016-11-30
CN106459955A (en) 2017-02-22
RU2702424C2 (en) 2019-10-08
RU2019130513A (en) 2019-10-10
TW201540724A (en) 2015-11-01
EP3118311A4 (en) 2017-10-11
RU2016139108A (en) 2018-04-13
CA2939948A1 (en) 2015-09-17
RS58573B1 (en) 2019-05-31
US9988629B2 (en) 2018-06-05
KR20160132056A (en) 2016-11-16
AU2015227733A1 (en) 2016-10-20
US20170067048A1 (en) 2017-03-09
TWI672314B (en) 2019-09-21
TW201945383A (en) 2019-12-01
TR201901939T4 (en) 2019-03-21
PH12016501761B1 (en) 2016-11-07
ZA201605864B (en) 2018-12-19
MY193708A (en) 2022-10-26
RU2019130513A3 (en) 2020-03-13
US11053497B2 (en) 2021-07-06
BR112016020618B1 (en) 2023-04-04
EP3118311A1 (en) 2017-01-18
WO2015137409A1 (en) 2015-09-17
SI3118311T1 (en) 2019-05-31
JP6606488B2 (en) 2019-11-13
CN110951732A (en) 2020-04-03
IL247663B (en) 2020-06-30
US20220162604A1 (en) 2022-05-26
CY1121322T1 (en) 2020-05-29
EP3118311B1 (en) 2018-12-26
PT3118311T (en) 2019-02-15
BR112016020618A8 (en) 2021-07-13
AU2015227733B2 (en) 2019-10-31
UA120849C2 (en) 2020-02-25
US20200149040A1 (en) 2020-05-14
ES2710802T3 (en) 2019-04-26
HRP20190235T1 (en) 2019-05-03
MX2016011538A (en) 2017-04-13
US20180179538A1 (en) 2018-06-28
AU2020200679A1 (en) 2020-02-20
EP3514234A1 (en) 2019-07-24
RU2016139108A3 (en) 2018-08-06
BR112016020618A2 (en) 2017-08-15
KR102335801B1 (en) 2021-12-03
AU2020200679B2 (en) 2022-03-10
HUE042283T2 (en) 2019-06-28
CN106459955B (en) 2019-12-20
LT3118311T (en) 2019-04-10
RU2730681C2 (en) 2020-08-24

Similar Documents

Publication Publication Date Title
HRP20190235T1 (en) Antisense nucleic acid
ZA201700142B (en) Antisense nucleic acids
DK3134131T3 (en) Nucleic acid vaccines
IL258065B (en) Antisense nucleic acids
GB201503408D0 (en) Oligonucleotides
IL257500A (en) Modified cullin1 gene
GB201517241D0 (en) DNA modification
SG11201700652PA (en) Modified antimir-138 oligonucleotides
GB2524076B8 (en) Improved Heater
GB201516505D0 (en) Antisense oligonucleotides
GB201508733D0 (en) Antisense oligonucleotides
GB201407865D0 (en) Nucleases
GB201403353D0 (en) Novel oligonucleotides
GB201403087D0 (en) Novel oligonucleotides
GB201403360D0 (en) Nucleic acids and uses thereof
GB201403359D0 (en) Nucleic acids and uses thereof